ELI LILLY AND COMPANY

TRD · Trade (domestic/foreign)

Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs

HCR · Health Issues

Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)

Literal federal measure citations: HR.5376, HR.1

MMM · Medicare/Medicaid

Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)

Literal federal measure citations: HR.5376, HR.1

CSP · Consumer Issues/Safety/Products

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality

CPT · Copyright/Patent/Trademark

Pharmaceutical intellectual property issues

TAX · Taxation/Internal Revenue Code

Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)

Literal federal measure citations: HR.1

PHA · Pharmacy

Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act